Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

August 16, 2017August 18, 2017

Fate’s NK Cell Therapy Successfully Administered to First AML Patient in Phase 1 Trial

News

The investigational adaptive memory natural killer (NK) therapy FATE-NK100 has been administered with success to the first acute myelogenous leukemia (AML) patient enrolled in the VOYAGE Phase 1 trial (NCT03081780), ... Read more

August 7, 2017August 7, 2017

B-Cell Non-Hodgkin Lymphoma Patients Begin Treatment with Axicabtagene Ciloleucel in Phase 2 Trial

News

Patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (iNHL) have begun treatment with axicabtagene ciloleucel (axi-cel) in the Phase 2 ZUMA-5 trial, the immunotherapy’s developer, Kite Pharma, announced. The trial (NCT03105336) is currently recruiting participants ... Read more

August 4, 2017August 4, 2017

FDA Approves Imbruvica for Adults with Chronic Graft-Versus-Host-Disease

News

The U.S. Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for patients with chronic graft-versus-host-disease (cGVHD) who failed to respond to other lines of therapy. With this decision, Imbruvica, already approved for ... Read more

July 19, 2017July 19, 2017

Intensifying Chemotherapy with Rituxan of Little Help to Advanced Hodgkins Lymphoma Patients, HD18 Trial Shows

News

Intensifying standard chemotherapy, known as escalated eBEACOPP, with the anti-CD20 antibody Rituxan (rituximab) showed no added benefit to progression-free survival in patients with advanced-stage Hodgkin’s lymphoma (HL), according to updated results ... Read more

July 11, 2017

FDA Will Review Application Seeking Approval of Truxima for Same Indications as Rituxan

News

The U.S. Food and Drug Administration has accepted for review the biologics license application (BLA) requesting the approval of Truxima (CT-P10), a biosimilar to Rituxan (rituximab), for the treatment of ... Read more

May 23, 2017May 23, 2017

Stem Cell Transplants May Not Extend Survival in DHL Patients in Remission, UPenn Study Suggests

News

Undergoing autologous stem-cell transplantation (autoSCT) after achieving remission does not extend remission or survival in patients with double hit lymphoma (DHL) — an aggressive form of B-cell non-Hodgkin lymphoma characterized by ... Read more

April 10, 2017

Variety of T-cells Linked to Better Survival in Non-Hodgkin’s Lymphoma, Study Shows

News

Patients with non-Hodgkin’s lymphoma show better chances of survival if they have a diverse variety of T-cells, are diverse, according to recent research from the University of Queensland, Australia. These ... Read more

July 1, 2016July 1, 2016

Hepatitis B- and C-Positive Patients Seem to Carry Higher Risks for Non-Hodgkin’s Lymphoma, According to Study

News

In an Italian case-control study with non-Hodgkin’s lymphoma (NHL) patients, researchers confirmed an increased risk for those positive for hepatitis C virus (HCV) and hepatitis B virus (HBV). The findings ... Read more

May 6, 2016May 6, 2016

Immunovaccine Launches DPX-NEO Program to Develop Immunotherapies for Cancer

News

Immunovaccine, Inc., has announced the launch of its DPX-NEO program to foster and expand its DepoVax-based vaccines for use in immuno-oncology clinical settings. The program was initiated to develop neoepitopes, molecules that are ... Read more

April 8, 2016April 8, 2016

Patient-reported Outcomes in Lymphoma Clinical Trials Are Recognized as Important Tools

News

Patient-reported outcomes in clinical trials of brentuximab vedotin for Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) show improvements in patients’ health-related quality of life, emphasizing their importance for patient management ... Read more